PPBT VS ABIO Stock Comparison

Performance

PPBT
10/100

PPBT returned -52.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ABIO
10/100

ABIO returned -13.17% in the last 12 months. Based on SPY's performance of 443.88%, its performance is below average giving it a score of 10 of 100.

Technicals

PPBT
11/100

PPBT receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

ABIO
11/100

ABIO receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

PPBT
10/100

PPBT has missed earnings 7 times in the last 20 quarters.

ABIO
100/100

ABIO has missed earnings 0 times in the last 20 quarters.

Profit

PPBT
11/100

Out of the last 20 quarters, PPBT has had 1 profitable quarters and has increased their profits year over year on 0 of them.

ABIO
10/100

Out of the last 20 quarters, ABIO has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

PPBT
48/100

PPBT has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

ABIO
59/100

ABIO has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.

Analyst Price Targets

PPBT

"Analyst Price Targets" not found for PPBT

ABIO
75/100

1 analysts offer 12-month price targets for ABIO. Together, they have an average target of 0, the most optimistic target put ABIO at 0 within 12-months and the most pessimistic has ABIO at 0.

All score calculations are broken down here to help you make more informed investing decisions

Purple Biotech Ltd. American Depositary Shares Summary

Nasdaq / PPBT

Healthcare

Biotechnology

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

ARCA biopharma, Inc. Summary

Nasdaq / ABIO

Healthcare

Biotechnology

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Power up your portfolio